- Zellweger spectrum disorders (ZSDs), a group of rare congenital peroxisomal biogenesis disorders, are gaining growing attention in the rare disease landscape due to increasing clinical recognition, research activity, and patient advocacy
- The rising demand for ZSD-related diagnostics and supportive treatments is primarily driven by improved access to genetic testing, growing awareness among healthcare professionals, and initiatives aimed at early detection through neonatal screening
- North America dominated the Zellweger spectrum disorders market with the largest revenue share of 39.4% in 2024, supported by robust healthcare infrastructure, ongoing clinical research, and proactive rare disease policy frameworks, particularly in the U.S., which benefits from strong collaborations between research institutions and patient organizations
- Asia-Pacific is expected to be the fastest growing region in the Zellweger spectrum disorders market during the forecast period, fueled by increasing investment in rare disease diagnostics, expanding healthcare access, and growing awareness among medical professionals in emerging economies
- Genetic Test segment dominated the Zellweger spectrum disorders market with a market share of 48.4% in 2024, driven by its high diagnostic accuracy and growing availability of advanced genomic technologies for early and definitive detection
